Efficacy and Safety of Tirofiban for Patients With BAD (BRANT)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 516 participants.
Also called NCT06037889
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 516 participants
- Registry
-
NCT06037889
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT06037889. Randomized; single masking; primary purpose treatment. Start 2023-11-09 (actual); primary completion 2026-02-26 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Tirofiban for Patients With BAD (BRANT)
- Acronym
- BRANT
- Condition
- Branch Atheromatous Disease
- Intervention (Drug)
- Tirofiban
- Intervention (Drug)
- Aspirin tablet
- Intervention (Drug)
- Clopidogrel tablet
- Lead sponsor
- Peking Union Medical College Hospital
- Collaborator
- Pharmaron (Chengdu) Clinical Services Co., Ltd.
Record details
- Record id
cardio:ct-nct06037889- Content hash
d5949b2db7f07505780f1c13b6716cdf73cac7b66096b1c7b97e7ccd9582e4e7